The Laboratory Sciences Core, Core D, under the direction of Dr Savita Pahwa (Director), Dr Rafick Sekaly (Co-Director), Dr. Geoffrey Stone (Core Coordinator) and recently recruited Co-Director of the CFAR, Dr Mario Stevenson will provide state-of-the-art assays in immunology, macrophage biology and molecular virology as well as expertise in systems biology. In the transition to a full CFAR, the Core has broadened its services to include systems biology and special virology. Core D laboratories that will serve the CFAR consist of I), the Immunology laboratory which performs specialized immunology assays and processes samples for the Miami CFAR biorepository;II), Sub-core 1, the Systems Biology Laboratory (new) at the Vaccine and Gene Therapy Institute (VGTI) in Port St. Lucie will provide consultation and bioinformatics support for gene array and related assays;HI), Sub-Core 2, the Special Virology Laboratory (new) that will offer molecular virology and purified myeloid-lineage cells by elutriation and IV, the CLIA approved Diagnostic Laboratory that performs routine CD4 and virus load assays and is also a back-up for cryopreservation of repository samples.
The specific Aims of Core D are: 1. To provide access to specialized, innovative and standardized immunologic assays for HIV/SIV immunopathogenesis and vaccine research, by providing immunologic services such as multiparameter flow cytometry, T- and B cell specific ELISPOT, assessment of cytokines, microbial translocation, thymus function, and immune monitoring protocols for investigations in human and non-human primate cells. The Core provides purified cell populations as well as protocols for manipulation (transfection, RNAi) of primary cells and links up investigators with specialized laboratories. 2. To provide capacity-building consultation for genomic assays and bioinformatic analysis performed at Vaccine and Gene Therapy Institute (VGTI) at Port St. Lucie, FL;3. To provide special virology and elutriated monocytes to CFAR investigators in the special virology sub-core. 4. To promote educational activities and to provide consultation/training for new CFAR-supported developmental grant awardees in collaboration with the Developmental Core, Core B and to T32 Trainees, 5. To assist in the CFAR objectives of developing scientific areas of research (SAR), by provision of laboratory resources to SAR members, and 6. To assist in development of repositories of clinical cohorts including HIV-negative and HIV-positive cohorts in collaboration with Clinical Sciences Core (Core C) and Behavioral and Social Sciences and Community Outreach Core (Core E).

Public Health Relevance

The proposed project is relevant to public health because it will establish a series of laboratory services and mechanisms to enhance HIV/AIDS research of established- as well as new investigators conducting AIDS research. This Core has a strong leadership and is critical for the success in attaining the collective goal of the Miami CFAR to discover novel means of prevention, treatment and ultimately cure HIV /AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI073961-06
Application #
8294239
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2012
Total Cost
$392,919
Indirect Cost
$91,636
Name
University of Miami School of Medicine
Department
Type
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Thomas, Emmanuel; Liang, T Jake (2016) Experimental models of hepatitis B and C - new insights and progress. Nat Rev Gastroenterol Hepatol 13:362-74
Metsch, Lisa R; Feaster, Daniel J; Gooden, Lauren et al. (2016) Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. JAMA 316:156-70
Liu, Albert Y; Cohen, Stephanie E; Vittinghoff, Eric et al. (2016) Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med 176:75-84
Kim, Ahrom; Han, Li; Santiago, Gabriel E et al. (2016) Class-Switch Recombination in the Absence of the IgH 3' Regulatory Region. J Immunol 197:2930-5
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Echenique, Marisa; Rodriguez, Violeta J; LaCabe, Richard P et al. (2016) Behaviorally and perinatally HIV-infected young women: targets for preconception counseling. AIDS Care :1-6
Peltzer, Karl; Rodriguez, Violeta J; Jones, Deborah (2016) Prevalence of prenatal depression and associated factors among HIV-positive women in primary care in Mpumalanga province, South Africa. SAHARA J 13:60-7
Cortizas, Elena M; Zahn, Astrid; Safavi, Shiva et al. (2016) UNG protects B cells from AID-induced telomere loss. J Exp Med 213:2459-2472
Strbo, Natasa; Alcaide, Maria L; Romero, Laura et al. (2016) Loss of Intra-Epithelial Endocervical Gamma Delta (GD) 1 T Cells in HIV-Infected Women. Am J Reprod Immunol 75:134-45
Pinto, Milena; Nissanka, Nadee; Peralta, Susana et al. (2016) Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation. Mol Neurodegener 11:25

Showing the most recent 10 out of 243 publications